ライフサイエンスコーパス: combination chemotherapy

1 readily AQ resistance will be selected with combination chemotherapy.

2 ategy B was fluorouracil until failure, then combination chemotherapy.

3 gents, doublets, triplets, and multiple drug combination chemotherapy.

4 general solution to delivering co-ordinated combination chemotherapy.

5 ersus FU; and gemcitabine versus gemcitabine combination chemotherapy.

6 sed after they received cisplatin-containing combination chemotherapy.

7 of highly active antiretroviral therapy and combination chemotherapy.

8 ssociated with poor response to conventional combination chemotherapy.

9 nts had a superior outcome when treated with combination chemotherapy.

10 ntrolled trials assessing fluorouracil-based combination chemotherapy.

11 h conventional-dose cisplatin-and-ifosfamide combination chemotherapy.

12 nical presentation and is more refractory to combination chemotherapy.

13 mice bearing MYC-driven SCLC beyond that of combination chemotherapy.

14 Acute toxic effects were more common with combination chemotherapy.

15 ed FL3 who received anthracycline-containing combination chemotherapy.

16 trials will explore rhuMAb VEGF alone and in combination chemotherapy.

17 re refractory to fludarabine at the start of combination chemotherapy.

18 ncer received four to six cycles of standard combination chemotherapy.

19 deliverable nanomedicines for more effective combination chemotherapy.

20 e form of LGL leukemia that was resistant to combination chemotherapy.

21 from adjuvant treatment with cisplatin-based combination chemotherapy.

22 of the fourth and final course of cisplatin combination chemotherapy.

23 an important agent to consider for trials of combination chemotherapy.

24 outine cures of human testicular tumors with combination chemotherapy.

25 sis, can serve as a model to further analyze combination chemotherapy.

26 further research on multidrug resistance and combination chemotherapy.

27 vents were as expected for pembrolizumab and combination chemotherapy.

28 egarding the safety and patient tolerance of combination chemotherapy.

29 RECIST responses were in patients receiving combination chemotherapy.

30 yeloid leukemia (AML) is anthracycline-based combination chemotherapy.

31 radiation therapy followed by six cycles of combination chemotherapy.

32 nts treated with adjuvant fluorouracil-based combination chemotherapy.

33 olds promise for optimization of anti-cancer combination chemotherapy.

34 er patients who cannot tolerate conventional combination chemotherapy.

35 l patients were treated with cisplatin-based combination chemotherapy.

36 s (P < .001); 89% of these patients received combination chemotherapy.

37 arly in patients who would otherwise receive combination chemotherapy.

38 est greater efficacy in treating tumors with combination chemotherapies.

39 ar and Hydrea, for antisense therapy, and in combination chemotherapies.

40 n over 80% of patients using cisplatin-based combination chemotherapy [1].

41 Standard (non-antimetabolite) combination chemotherapy administered past the first tri

42 re immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in pat

43 mechanisms of resistance and optimize future combination chemotherapy against MM.

44 Combination chemotherapy alone including gemcitabine, a

45 CVAD combination chemotherapy alone or with the chemosensitiz

46 pursue to avoid this complication is to use combination chemotherapy alone, especially in young wome

47 sitive, with a high overall response rate to combination chemotherapy and a minority of complete resp

48 line of at least 12 weeks of taxane-platinum combination chemotherapy and achieved partial or complet

49 Clinicians should offer combination chemotherapy and an HER2-targeted agent as i

50 s the majority of afflicted patients despite combination chemotherapy and hematopoietic cell transpla

51 tic interactions resulting from simultaneous combination chemotherapy and highly active antiretrovira

52 Three studies used a cisplatin-containing combination chemotherapy and included primarily patients

53 sive treatment with anthracycline-containing combination chemotherapy and involved-field radiation th

54 adolescents with Hodgkin's disease includes combination chemotherapy and low-dose involved-field rad

55 wed similar response rates to platinum-based combination chemotherapy and no difference in overall su

56 hod (TITE-CRM) for dose-escalation trials of combination chemotherapy and radiation.

57 Even with combination chemotherapy and radiotherapy treatments, th

58 rwent extrapleural pneumonectomy followed by combination chemotherapy and radiotherapy.

59 abine after progression after both cisplatin combination chemotherapy and subsequent high-dose chemot

60 Initial therapy included combination chemotherapy and surgery.

61 Cisplatin-based combination chemotherapy and the refinement of post-chem

62 Eight had progressed after intensive combination chemotherapy and three after allogeneic or a

63 ad received first-line taxane/platinum-based combination chemotherapy and were platinum refractory or

64 treated as primary therapy responded to the combination chemotherapy and were preserved.

65 ith GCT who progressed after cisplatin-based combination chemotherapy and were subsequently treated w

66 We advocate earlier inclusion of combinations +/- chemotherapy and of newly diagnosed pat

67 agnosed in 1995, 40% received tamoxifen, 16% combination chemotherapy, and 7% both, an increase from

68 isk of graft rejection, anti-CD20 treatment, combination chemotherapy, and administration of EBV-spec

69 Multisystem disease should be treated with combination chemotherapy, and current experimental thera

70 ciated with unfavorable responses to empiric combination chemotherapy, and defining robust subtypes w

71 if they were treated for lymphoma, received combination chemotherapy, and did not develop therapy-re

72 Single agent is preferable to combination chemotherapy, and longer planned duration im

73 ggest a broader perspective on the design of combination chemotherapy approaches with immediate clini

74 ng considerations for the modern practice of combination chemotherapy are also discussed.

75 itial treatment: Three patients who received combination chemotherapy are currently alive and free of

76 Studies involving combination chemotherapy are ongoing, and preliminary re

77 Glucocorticoids (GCs) are used in combination chemotherapies as front-line treatment for B

78 dvanced NSCLC and PS 2 are best treated with combination chemotherapy as first-line therapy.

79 with radiation therapy, and 46 also received combination chemotherapy as part of their initial treatm

80 d-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Tre

81 ication of systemic therapy with neoadjuvant combination chemotherapy before standard treatment is fe

82 He was successfully treated with combination chemotherapy but unfortunately died, 6 month

83 d with similar response rates as neoadjuvant combination chemotherapy but with significantly lower to

84 Combination chemotherapy can increase treatment efficacy

85 contrasting approaches: a single agent, and combination chemotherapy capable of curing diffuse aggre

86 tic infections were examined with the use of combination chemotherapy combined with HAART.

87 mized controlled phase III trial of adjuvant combination chemotherapy compared gemcitabine and capeci

88 Survival was improved after gemcitabine combination chemotherapy compared with gemcitabine alone

89 (95% CI, 0.38 to 0.67) with cisplatin-based combination chemotherapy compared with hydroxyurea.

90 authors introduce the innovative concept of combination chemotherapy consisting of 2 antimetabolites

91 Patients were treated with combination chemotherapy consisting of cyclophosphamide,

92 ial escalation therapy compared with initial combination chemotherapy could not be demonstrated for T

93 Combination chemotherapy could overcome drug resistance;

94 We investigated whether preparative combination chemotherapy could replace TBI in such patie

95 ith a single-alkylating agent nor aggressive combination chemotherapy cures advanced stage low-grade

96 FU-based combination chemotherapy did not result in better overal

97 whom clonal Ig DNA remained detectable after combination chemotherapy died with lymphoma.

98 resentation, and three patients who received combination chemotherapy died within 5 months of present

99 patients received a median of four cycles of combination chemotherapy during pregnancy.

100 tment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years.

101 apy, similarly failed to show monotherapy or combination chemotherapy efficacy in a model of postsurg

102 ) intravenous), followed by three courses of combination chemotherapy (either cyclophosphamide, doxor

103 ical series to be investigated in single and combination chemotherapies, especially targeting hematol

104 hese spheroids were then dosed with a common combination chemotherapy, FOLFIRI (folinic acid, 5-fluor

105 cT2-T4a N0M0) is neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy.

106 ree cycles of anthracycline-cyclophosphamide combination chemotherapy followed by three cycles of tax

107 Several docetaxel-based combination chemotherapies for hormone refractory prosta

108 The role of combination chemotherapy for advanced bladder cancer con

109 We present our experience with the use of combination chemotherapy for breast cancer during pregna

110 amethasone (dex), are a central component of combination chemotherapy for childhood B-cell precursor

111 ed risk of second tumors after sequential or combination chemotherapy for GTT.

112 rone, Oncovin, Velban, and Prednisone (NOVP) combination chemotherapy for Hodgkin's disease increases

113 improved by the addition of immunotherapy to combination chemotherapy for initial treatment in all su

114 g-term complications of intensive rotational combination chemotherapy for late hematologic relapse (m

115 We conclude that patients treated with PI combination chemotherapy for LR or HR WT or clear cell s

116 up of 6.2 years on (1) the role of intensive combination chemotherapy for older patients with AML, (2

117 Among the women who received platinum-based combination chemotherapy for ovarian cancer, the relativ

118 goal of this study was to identify effective combination chemotherapy for pancreatic cancer using pan

119 ative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue s

120 and safety of irinotecan and gemcitabine as combination chemotherapy for previously untreated patien

121 Platinum-based combination chemotherapy for PS-2 patients with NSCLC is

122 e) in patients receiving 5 days of cisplatin combination chemotherapy for testicular cancer.

123 se of existing compounds, either alone or in combination chemotherapy, for improved efficacy and safe

124 Strategy C was combination chemotherapy from the outset.

125 supportive care; fluorouracil (FU) versus FU combination chemotherapy; gemcitabine versus FU; and gem

126 hough most patients are cured with intensive combination chemotherapy, given the paucity of randomize

127 Performance status 2 patients treated with combination chemotherapy had a better survival rate than

128 Recently, vinorelbine and cisplatin combination chemotherapy has been shown for the first ti

129 Since the 1960s, combination chemotherapy has been widely utilized as a s

130 The response of liver metastases to systemic combination chemotherapy has improved, but the 2-year su

131 Whereas cisplatin-paclitaxel combination chemotherapy has shown significant efficacy

132 t trial suggests that carboplatin/ifosfamide combination chemotherapy has substantial antitumor activ

133 upplant single radioisotope therapy, much as combination chemotherapy has substantially replaced sing

134 Combination chemotherapies have been a mainstay in the t

135 ttempts to add molecular-targeted therapy to combination chemotherapy have failed except for bevacizu

136 Therapeutic outcomes of combination chemotherapy have not significantly advanced

137 th RAS/BRAF wild-type tumors benefitted from combination chemotherapy (HR, 0.61; 90% CI, 0.46 to 0.82

138 he addition of thoracic radiation therapy to combination chemotherapy improved both complete response

139 Combination chemotherapy improves response rate and fail

140 to assess the penetration and metabolism of combination chemotherapies in three-dimensional colon ca

141 eceived antenatal therapy (doxorubicin based combination chemotherapy in 20 of 24 patients), and 12 d

142 markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU-resistant metastatic co

143 urvival were longer among those who received combination chemotherapy in addition to radiation therap

144 gent before initiating therapy with standard combination chemotherapy in metastatic breast cancer pat

145 gylated-liposomal doxorubicin, with standard combination chemotherapy in patients with advanced AIDS-

146 Adding blinatumomab to combination chemotherapy in patients with newly diagnose

147 effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, per

148 The addition of bevacizumab to combination chemotherapy in patients with recurrent, per

149 r activity and safety of targeted therapy or combination chemotherapy in progressive desmoid tumours.

150 rmed chemosensitive with the introduction of combination chemotherapy in the 1970s.

151 s to define the contribution of docetaxel to combination chemotherapy in the outcome of patients with

152 This supports the use of gemcitabine-based combination chemotherapy in the treatment of advanced pa

153 of several trials have evaluated the use of combination chemotherapy in this difficult subgroup of p

154 er investigation of gemcitabine-based RT and combination chemotherapy in this disease.

155 This trial (NSABP B-38; Combination Chemotherapy in Treating Women Who Have Unde

156 could be combined with traditional forms of combination chemotherapy in which two or more compounds

157 Combination chemotherapy, in which two or more drugs are

158 association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02)

159 We discuss bladder preserving approaches, combination chemotherapy including new agents, targeted

160 Combination chemotherapy, including the recently develop

161 We propose a strategy of combination chemotherapy incorporating the use of multip

162 this study, the addition of immunotherapy to combination chemotherapy increased toxicity but did not

163 situ hybridization (RNA-ISH) that FOLFIRINOX combination chemotherapy induces a common shift of both

164 Gemcitabine-platinum combination chemotherapy initiated within 90 days after

165 Combination chemotherapy is a useful approach for patien

166 Combination chemotherapy is an important protocol in gli

167 d testicular germ cell tumors with cisplatin combination chemotherapy is based on risk stratification

168 Combination chemotherapy is commonly used to treat advan

169 Cisplatin-based combination chemotherapy is considered standard first-li

170 n in stage II disease, and oxaliplatin-based combination chemotherapy is now routinely used for stage

171 Single-agent or combination chemotherapy is often indicated for such pat

172 Cisplatin-based combination chemotherapy is the foundation for treatment

173 Combination chemotherapy is the leading clinical option

174 oma, and further evaluation of this agent in combination chemotherapy is warranted.

175 ole for combined modality therapy, including combination chemotherapy, is being explored.

176 Front-line platinum-based combination chemotherapy leads to high response rates bu

177 The potential benefit of adding rituximab to combination chemotherapy may be offset by infectious com

178 Recent evidence suggests combination chemotherapy may help some patients, althoug

179 Dose-dense (DD) regimens of combination chemotherapy may produce superior clinical o

180 Nevertheless, rituximab and combination chemotherapy may transiently clear PB or BM

181 pite being initially responsive to intensive combination chemotherapy, most patients relapse and succ

182 Thus, combination chemotherapy must be optimized to increase t

183 Combination chemotherapy must strike a difficult balance

184 Compared with combination chemotherapy, NET as monotherapy with aromat

185 us, stage IV CRC who receive up-front modern combination chemotherapy never require palliative surger

186 Glucocorticoids are extensively used in combination chemotherapy of advanced prostate cancer (PC

187 The combination chemotherapy of FFG was well tolerated and m

188 The effects of combination chemotherapy of HDAC inhibitors and anthracy

189 offer our best hope for treatment-shortening combination chemotherapy of TB.

190 omic profiling to examine the effects of the combination chemotherapy on the colon cancer cells.

191 sease had relapsed or progressed after prior combination chemotherapy or anthracycline therapy.

192 to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an aut

193 litaxel/bevacizumab, platinum-based two-drug combination chemotherapy, or non-platinum-based two-drug

194 cal excision for localized disease; surgery, combination chemotherapy, or prednisone for multicentric

195 roach of surgical cytoreduction and adjuvant combination chemotherapy, ovarian cancer mortality remai

196 rial to demonstrate a survival advantage for combination chemotherapy over cisplatin alone in advance

197 , surgical techniques, radiation therapy and combination chemotherapy over the past decades.

198 iver metastases in 2009 and 2010, palliative combination chemotherapy (oxaliplatin plus capecitabine)

199 with 9 of 27 (33%) treated with conventional combination chemotherapy (P = .036) despite similar tran

200 5-fluorouracil-doxorubicin-cyclophosphamide combination chemotherapy (P = 0.0048), particularly agai

201 We prospectively studied the use of combination chemotherapy plus cranial irradiation in new

202 ing standard combination chemotherapy versus combination chemotherapy plus flavopiridol is currently

203 ndomly assigned in nine trials that compared combination chemotherapy plus tamoxifen with tamoxifen a

204 cted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is s

205 This combination chemotherapy previously showed synergistic p

206 survival during a second round of intensive combination chemotherapy (probability of survival: 6-BG/

207 Combination chemotherapy produces a significant decrease

208 PAC combination chemotherapy produces response rates in the

209 w indicate that the addition of rituximab to combination chemotherapy prolongs progression-free and o

210 Compared with patients receiving combination chemotherapy protocols, those treated with s

211 f 65 or considered to be poor candidates for combination chemotherapy received docetaxel 36 mg/m2 wee

212 e effective and less toxic than the standard combination chemotherapy regimen ABV for treatment of AI

213 Combination chemotherapy regimen incorporating CD20 anti

214 totoxic agents, such as the recent promising combination chemotherapy regimen of folinic acid (leucov

215 apy can safely be eliminated from front-line combination chemotherapy regimens for advanced Hodgkin's

216 orticoid treatment, one of the components of combination chemotherapy regimens for lymphoma.

217 ts with high-risk metastatic disease receive combination chemotherapy regimens from the start.

218 rials of comparative standard platinum-based combination chemotherapy regimens have demonstrated infe

219 The use of pediatric intensive combination chemotherapy regimens in adolescents and you

220 Glucocorticoids are critical components of combination chemotherapy regimens in pediatric acute lym

221 Combination chemotherapy regimens including irinotecan a

222 le warrants further investigation, either in combination chemotherapy regimens or with targeted biolo

223 The rapid expansion in the use of improved combination chemotherapy regimens plus or minus biologic

224 boratory studies in the course of developing combination chemotherapy regimens that consist of topo I

225 might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR acti

226 algorithm to determine the emetogenicity of combination chemotherapy regimens was then designed by c

227 since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for an

228 Combination chemotherapy regimens were superior to singl

229 tinum drugs should be included in studies of combination chemotherapy regimens wherever possible.

230 Retrospective studies suggest a benefit for combination chemotherapy regimens.

231 inuously developing new anticancer drugs and combination chemotherapy regimens.

232 e optimal dose and schedule of paclitaxel in combination chemotherapy remain to be established.

233 Platinum and etoposide combination chemotherapy remains the standard of care in

234 Combination chemotherapy represents the standard-of-care

235 ddition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically signif

236 When selecting combination chemotherapy salvage options, evaluation of

237 clinical studies that show the importance of combination chemotherapy, sanctuary-specific treatment,

238 After combination chemotherapy, six patients (three FLT3-ITD a

239 emale; age range, 12-42 y) were treated with combination chemotherapy (standard U.K. protocol) and (1

240 We compared sequential and combination chemotherapy strategies in patients with unp

241 ilable, including single-agent chemotherapy, combination chemotherapy strategies, radiotherapy, the i

242 nucleoside analogs plus alkylator agents, or combination chemotherapies, such as CHOP (cyclophosphami

243 was normalized with actinomycin D (42.3%) or combination chemotherapy/surgery (57.1%).

244 le potential signaling targets for designing combination chemotherapies that could inhibit the synerg

245 opportunities for enhanced lymphoid-specific combination chemotherapies that have the potential to ov

246 o carefully evaluate the clinical effects of combination chemotherapies that incorporate antiangiogen

247 majority of patients (80%) were treated with combination chemotherapy that included an anthracycline,

248 10), patients received 44 weeks of identical combination chemotherapy that included high-dose methotr

249 This strategy should be compared with combination chemotherapy, the current standard of care.

250 Despite advances in combination chemotherapy, the overall survival for child

251 al chemoimmunotherapy included two cycles of combination chemotherapy, then an intradermal lower abdo

252 The relative value of gemcitabine-based combination chemotherapy therapy and prolonged infusions

253 We extend our approach of combination chemotherapy through a single prodrug entity

254 The ability of combination chemotherapy to cure acute childhood leukemi

255 Such a compound may be useful in novel combination chemotherapy to enhance the efficacy of alky

256 rapy, but it is being increasingly used with combination chemotherapy to improve the objective respon

257 t EZH2 phosphorylation should be included in combination chemotherapy to increase therapeutic index.

258 ible, HIV-1-infected patients should receive combination chemotherapy to minimize the emergence of re

259 CLC), shifting treatment from platinum-based combination chemotherapy to molecularly tailored therapy

260 The addition of combination chemotherapy to standard radiation therapy h

261 al appears to be improved by the addition of combination chemotherapy to tamoxifen.

262 Combination chemotherapy trials do not demonstrate a con

263 rivatives, as well as older single-agent and combination chemotherapy trials.

264 These findings suggest that combination chemotherapy used to treat children with ALL

265 y, and those who have high-risk disease with combination chemotherapy using etoposide, methotrexate a

266 Combination chemotherapy using paclitaxel with a platinu

267 recommend induction therapy with multi-agent combination chemotherapies (usually selected from bortez

268 esults, a phase III trial comparing standard combination chemotherapy versus combination chemotherapy

269 We compared the efficacy of combination chemotherapy versus single-agent therapy in

270 osed between 2002 and 2007, bevacizumab with combination chemotherapy was associated with improved ov

271 The addition of bevacizumab to cytotoxic combination chemotherapy was associated with small impro

272 Combination chemotherapy was initiated, and the cutaneou

273 By employing a "mechanism-based approach" to combination chemotherapy, we show that ceftazidime-aviba

274 initial complete response after risk-adapted combination chemotherapy were randomized to receive LD-I

275 ic colorectal cancer previously treated with combination chemotherapy were randomly assigned 1:1 to r

276 Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with

277 Combination chemotherapy with bevacizumab and erlotinib

278 Combination chemotherapy with bevacizumab, versus combin

279 Combination chemotherapy with CP significantly improves

280 The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubi

281 troviral therapy (HAART) alone to HAART with combination chemotherapy with doxorubicin, bleomycin and

282 Combination chemotherapy with gemcitabine, carboplatin,

283 Combination chemotherapy with HDPEB significantly improv

284 seful in designing future clinical trials of combination chemotherapy with l-OddC and CPT analogs wit

285 ingle-agent cisplatin (70 mg/m2 on day 1) or combination chemotherapy with methotrexate (30 mg/m2 on

286 andomized intergroup trial demonstrated that combination chemotherapy with methotrexate, vinblastine,

287 of multimodality approaches, often including combination chemotherapy with or without radiation thera

288 e III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Thera

289 amples from 1,282 patients enrolled onto the Combination Chemotherapy With or Without Trastuzumab in

290 Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab in

291 eplication-competent vectors was superior to combination chemotherapy with paclitaxel and carboplatin

292 Combination chemotherapy with purine analogues is showin

293 apy alone followed by six cycles of standard combination chemotherapy with the same anti-HER2 therapy

294 dependency to optimize the effectiveness of combination chemotherapy with Topo I and Topo II inhibit

295 Combination chemotherapy with VBL and MTX appears to con

296 Extensive-stage disease should be managed by combination chemotherapy, with a regimen such as etoposi

297 e treatment approach for many years has used combination chemotherapy, with usually an anthracycline

298 nation chemotherapy with bevacizumab, versus combination chemotherapy without bevacizumab, was associ

299 cancer (CRC) and who receive up-front modern combination chemotherapy without prophylactic surgery.

300 Combination chemotherapy yields a response rate of 24% a